{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-24-000523","form_type":"8-K","ticker":"TENX","cik":"0000034956","company_name":"TENAX THERAPEUTICS, INC.","filed_at":"2024-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.569920+00:00","generated_at":"2026-06-07T00:11:48.120809+00:00","sec_items":["3.01","5.02","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Tenax Therapeutics receives Nasdaq delisting notice; appoints interim CFO Lawrence Hoffman","bullets":["Nasdaq notified Tenax on Jan 11, 2024 that it fails minimum 500,000 publicly held shares after 1-for-80 reverse split.","Company has until Feb 26, 2024 to submit a compliance plan; no immediate effect on listing or trading.","Lawrence Hoffman appointed Interim CFO effective Jan 11, 2024, succeeding Eliot Lurier (deceased).","Hoffman will be paid $416/hour through Danforth Advisors consulting agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-24-000523","json":"https://secwatch.observer/filing/0001654954-24-000523.json","markdown":"https://secwatch.observer/filing/0001654954-24-000523.md","text":"https://secwatch.observer/filing/0001654954-24-000523.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/34956/000165495424000523/0001654954-24-000523-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/34956/000165495424000523/tenx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T00:11:48.120809+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2f945f49d23b40e56c5db95ed3e08fb05365c230","claim":"TENAX THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding other (rules 5550(a)(4)).","evidence_excerpt":"January 11, 2024, Tenax Therapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) regarding compliance with Nasdaq Listing Rule 5550(a)(4) (the “Rule”) which requires the Company to have a minimum of 500,000 publicly held shares. The letter from Nasdaq indicated that according to its calculations, as of January 3, 2024, the day after the Company effected a 1-for-80 reverse split of its common stock, the Company no longer meets the requirements of the Rule. This notice of noncompliance has no immediate impact on the cont","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/34956/000165495424000523/0001654954-24-000523-index.htm","confidence":0.98,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Rules","value":"5550(a)(4)"}],"fact_type":"exchange_compliance_notice"},{"claim_id":"4e355a8b24","claim":"Eliot M. Lurier departed as Chief Financial Officer at TENAX THERAPEUTICS, INC..","evidence_excerpt":"Mr. Hoffman succeeds Eliot M. Lurier, who passed away in December 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/34956/000165495424000523/0001654954-24-000523-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"passed away"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"c947e3daf6","claim":"Lawrence R. Hoffman was appointed as Interim Chief Financial Officer at TENAX THERAPEUTICS, INC..","evidence_excerpt":"On January 9, 2024, the Company’s Board of Directors (the “Board”) appointed Lawrence R. Hoffman as Interim Chief Financial Officer of the Company effective January 11, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/34956/000165495424000523/0001654954-24-000523-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}